Ken Griffin Moon Lake Immunotherapeutics Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Citadel Advisors LLC holds 17,300 shares of MLTX stock, worth $956,344. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,300
Previous 30,200
42.72%
Holding current value
$956,344
Previous $1.52 Million
49.87%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding MLTX
# of Institutions
127Shares Held
58MCall Options Held
103KPut Options Held
79.7K-
Bvf Inc San Francisco, CA21.8MShares$1.2 Billion29.25% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$470 Million28.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$153 Million1.66% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.56MShares$142 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.83MShares$101 Million0.15% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.04B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...